Impetigo is a bacterial skin condition common in children and characterized by blisters that may itch. Now there is a new antibacterial ointment approved to treat this condition. Retapamulin (Altabax 1%, GlaxoSmithKline) is the first of a new class of antibacterials known as pleuromutilins. According to the manufacturer, no other antibacterials use the same specific mode of action.
The activeingredient works by binding toa site on the 50S subunit ofthe bacterial ribosomeand inhibits proteinsynthesis through aninteraction with theribosome. Retapamulin isapproved for the treatment ofimpetigo due to susceptiblestrains of S. aureus or S. pyogenesin patients nine months of age or older. The ointmentshould be applied twice daily for five days.
FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
April 29th 2024The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.
Examining the State of Benzoyl Peroxide-Containing Acne Products After Benzene Contamination
April 10th 2024Christopher Bunick, MD, PhD, FAAD, an associate professor of dermatology and a physician-scientist at the Yale School of Medicine in New Haven, Connecticut, presented updates on benzene in BPO at the 2024 American Academy of Dermatology Annual Meeting.